Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 6/20 | 0.40 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179060 | 0.89 | AR (0.43) | S1PR1PPARGAR | |
| SCHEMBL4182274 | 0.85 | AR (0.41) | AR | |
| SCHEMBL4187001 | 0.84 | S1PR1 (0.35) | S1PR1ARMCL1 | |
| SCHEMBL4174163 | 0.84 | ACHE (0.42) | AR | |
| SCHEMBL4183677 | 0.82 | TACR1 (0.40) | — | |
| SCHEMBL4180847 | 0.81 | TACR1 (0.37) | — | |
| SCHEMBL4182498 | 0.72 | AR (0.41) | AR | |
| SCHEMBL7237834 | 0.72 | PPARG (0.57) | PPARGMCL1 | |
| SCHEMBL4169607 | 0.71 | AR (0.41) | S1PR1ARGPR17 | |
| SCHEMBL4186729 | 0.69 | AR (0.42) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | claimed |
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| WO-2007005887-A2 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS, COMPOSITIONS AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | S1PR1 1301/4885PPARG 65/4885AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.